Programs

  • Program 1 [2020]

    The organization has continued to develop utilization of its lead product, a vaccine adjuvant which enhances the humoral, cellular, and mucosal immunity raised by a given vaccine.
    Geographies
    Not indicated
    Dates
    Jan 1, 2020 – Dec 31, 2020
    Source
    990
    No causes provided
    No populations provided
    –
    $29.4K

  • Vaccine Adjuvant Development

    The organization has continued to develop utilization of its lead product, a vaccine adjuvant which enhances the humoral, cellular, and mucosal immunity raised by a given vaccine.
    Geographies
    Not indicated
    Dates
    Jan 1, 2022 – Dec 31, 2022
    Source
    990
    No causes provided
    No populations provided
    –
    $25.2K